rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study

rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study

Background: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of common profibrotic polymorphisms in MUC5B (mucin 5B, rs35705950) and DSP (desmoplakin, rs2076295) on antifibrotic treatment outcomes in IPF....

Full description

Bibliographic Details
Main Authors: Martina Doubkova, Eva Kriegova, Simona Littnerova, Petra Schneiderova, Martina Sterclova, Vladimir Bartos, Martina Plackova, Monika Zurkova, Radka Bittenglova, Vladimira Lostaková, Lenka Siskova, Pavlina Lisa, Hana Suldova, Michael Doubek, Jana Psikalova, Tomas Snizek, Pavlina Musilova, Martina Vasakova
Format: Article
Language:English
Published: SAGE Publishing 2021-09-01
Series:Therapeutic Advances in Respiratory Disease
Online Access:https://doi.org/10.1177/17534666211042529

Internet

https://doi.org/10.1177/17534666211042529

Similar Items